Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide.
No risks detected for NZYM from our risk checks.
Excellent balance sheet with reasonable growth potential and pays a dividend.
Share Price & News
How has Novozymes's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NZYM has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NZYM exceeded the Austrian Chemicals industry which returned 9.5% over the past year.
Return vs Market: NZYM exceeded the Austrian Market which returned 3.5% over the past year.
Price Volatility Vs. Market
How volatile is Novozymes's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Novozymes undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: NZYM (€50) is trading above our estimate of fair value (€33.88)
Significantly Below Fair Value: NZYM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NZYM is poor value based on its PE Ratio (33.9x) compared to the Chemicals industry average (16.3x).
PE vs Market: NZYM is poor value based on its PE Ratio (33.9x) compared to the Austrian market (14.1x).
Price to Earnings Growth Ratio
PEG Ratio: NZYM is poor value based on its PEG Ratio (7.8x)
Price to Book Ratio
PB vs Industry: NZYM is overvalued based on its PB Ratio (9.2x) compared to the XE Chemicals industry average (1.6x).
How is Novozymes forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NZYM's forecast earnings growth (4.3% per year) is above the savings rate (-0.1%).
Earnings vs Market: NZYM's earnings (4.3% per year) are forecast to grow faster than the Austrian market (2.3% per year).
High Growth Earnings: NZYM's earnings are forecast to grow, but not significantly.
Revenue vs Market: NZYM's revenue (4.7% per year) is forecast to grow faster than the Austrian market (2.7% per year).
High Growth Revenue: NZYM's revenue (4.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NZYM's Return on Equity is forecast to be high in 3 years time (31%)
How has Novozymes performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NZYM has high quality earnings.
Growing Profit Margin: NZYM's current net profit margins (21.9%) are lower than last year (22.4%).
Past Earnings Growth Analysis
Earnings Trend: NZYM's earnings have grown by 4.3% per year over the past 5 years.
Accelerating Growth: NZYM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NZYM had negative earnings growth (-2.2%) over the past year, making it difficult to compare to the Chemicals industry average (2.5%).
Return on Equity
High ROE: NZYM's Return on Equity (27.5%) is considered high.
Return on Assets
Return on Capital Employed
How is Novozymes's financial position?
Financial Position Analysis
Short Term Liabilities: NZYM's short term assets (DKK7.1B) exceed its short term liabilities (DKK4.7B).
Long Term Liabilities: NZYM's short term assets (DKK7.1B) exceed its long term liabilities (DKK4.2B).
Debt to Equity History and Analysis
Debt Level: NZYM's debt to equity ratio (35.6%) is considered satisfactory.
Reducing Debt: NZYM's debt to equity ratio has increased from 15.9% to 35.6% over the past 5 years.
Debt Coverage: NZYM's debt is well covered by operating cash flow (78.2%).
Interest Coverage: NZYM earns more interest than it pays, so coverage of interest payments is not a concern.
Inventory Level: NZYM has a high level of physical assets or inventory.
Debt Coverage by Assets: NZYM's debt is covered by short term assets (assets are 1.7x debt).
What is Novozymes's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Purchase Novozymes before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: NZYM's dividend (1.4%) isn’t notable compared to the bottom 25% of dividend payers in the Austrian market (1.58%).
High Dividend: NZYM's dividend (1.4%) is low compared to the top 25% of dividend payers in the Austrian market (4.58%).
Stability and Growth of Payments
Stable Dividend: NZYM's dividends per share have been stable in the past 10 years.
Growing Dividend: NZYM's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (47.5%), NZYM's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: NZYM's dividends in 3 years are forecast to be covered by earnings (50.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ester Baiget 0
Ms. Ester Baiget serves as Chief Executive Officer at Novozymes A/S Since February 1, 2020 and its President since 2020. She serves as the EMEA Commercial Director for Dow Elastomers, Electrical and Teleco ...
|Executive VP & CFO||0.4yrs||ø4.20m||0.00035% DKK49.6k|
|Exectuive VP & COO of Research||0yrs||ø10.50m||no data|
|Executive Vice President of Food & Beverages||4yrs||ø7.50m||0.0012% DKK175.7k|
|Executive Vice President of Household Care & Technical Industries||4yrs||ø7.70m||0.000050% DKK7.1k|
|Executive Vice President of Agriculture & Bioenergy||4yrs||ø7.60m||0.0036% DKK510.0k|
|President & CEO||0yrs||no data||no data|
|Head of Investor Relations||0yrs||no data||no data|
|Vice President of Global Sales & Marketing||0yrs||no data||no data|
|Head of Corporate Affairs & Sustainability - Novozymes Latin America||0yrs||no data||no data|
|VP and Head of New Business Development - Incubations & Acquisitions||0yrs||no data||no data|
Experienced Management: NZYM's management team is considered experienced (4 years average tenure).
|Independent Director||13.1yrs||ø500.00k||0.00023% DKK32.6k|
|Employee Representative Director||10.1yrs||ø500.00k||0.00013% DKK18.4k|
|Independent Vice Chairman||0yrs||ø1.35m||0.00015% DKK21.2k|
|Independent Chairman||3yrs||ø1.75m||0.00071% DKK100.6k|
|Independent Director||3yrs||ø750.00k||no data|
|Employee Representative Director||7yrs||ø500.00k||0.00039% DKK55.2k|
|Employee Representative Director||7yrs||ø500.00k||0.00013% DKK18.4k|
Experienced Board: NZYM's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Novozymes A/S's company bio, employee growth, exchange listings and data sources
- Name: Novozymes A/S
- Ticker: NZYM
- Exchange: WBAG
- Founded: 1925
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: ø105.880b
- Listing Market Cap: ø14.166b
- Shares outstanding: 282.35m
- Website: https://www.novozymes.com
Number of Employees
- Novozymes A/S
- Krogshoejvej 36
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NVZM.F||OTCPK (Pink Sheets LLC)||Yes||Series B Shares||US||USD||Nov 2000|
|NZM2||DB (Deutsche Boerse AG)||Yes||Series B Shares||DE||EUR||Nov 2000|
|NZYM B||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Series B Shares||DK||DKK||Nov 2000|
|0Q4U||LSE (London Stock Exchange)||Yes||Series B Shares||GB||DKK||Nov 2000|
|NZYMBC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Series B Shares||GB||DKK||Nov 2000|
|NZYMB||SWX (SIX Swiss Exchange)||Yes||Series B Shares||CH||CHF||Nov 2000|
|NZYM||WBAG (Wiener Boerse AG)||Yes||Series B Shares||AT||EUR||Nov 2000|
|NZYM N||BMV (Bolsa Mexicana de Valores)||Yes||Series B Shares||MX||MXN||Nov 2000|
|NVZM.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||Feb 2003|
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefaction, saccharifaction, fermentation, lignecellulosic hydrolysis, and process enhancement solutions for bioenergy; baking, beverages, dairy, starch, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising denim finishing and abrasion, biopreparation, biopolishing bleach clean-up, and desizing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rTrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research, development, production, marketing, and sale of a portfolio of probiotic products; and development agreement with CARBIOS to produce enzyme for recycling of pet-plastics and fibers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/22 22:47|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.